Close

Commitment and Awards

The corporate governance is guided by company mission of the founder G. Lorenzini, “Fare per dare” as it can be seen in its commitment to and investments in initiatives inspired by the values that have led IBI for 100 years.

  • Youth training and research, with the promotion of scholarships, masters and engagement in work experience projects
  • Diffusion of pharmaceutical culture and activities in developing countries, with projects that enable students to return to their home countries and open businesses that foster the development of the local economy;
  • The battle to raise awareness on appropriate treatments and the diffusion among young people and their families of the correct use of antibiotics, to help to prevent the emergence of resistance to antibiotics. An example is the teaching programme created in partnership with the Explora children’s museum in Rome.

AWARDS

The commitment of the IBI team has been acknowledged and awarded over the years. Among the various awards received:

  • Premio Randstad Globe: the IBI Human Resources area was awarded for its ability to create value in youth training thanks to the trainees’ involvement in the business culture and teamwork.
  • La Mela d’Oro (Marisa Bellisario Award) for female entrepreneurship: to the IBI chairperson and managing director, as an example of female leadership in the pharmaceutical sector. Women make up 44% of all the company’s employees and over 50% of the R&D team. “Camilla Borghese Khevenhüller demonstrates,” this is the reason for the award, “how women in top positions are determining in making pharmaceutical companies more competitive and innovative in Italy”.
  • 100 Eccellenze Italiane: IBI was awarded the prestigious prize for Italian-made products, devised by the publishers Dell'Anna to pay homage to those companies and personalities whose work and creativity contribute to the growth of Italian know-how in the world.

Latest news

undefined

REVER3MAB: "An ambitious project for the development of an innovative biological drug"?

IBI collaborates in the development of an innovative biological drug to revert resistance to conventional cancer treatments: project: REVER3MAB (EU, State and Region)

Read all
undefined

Seguiamo i farmaci fino a voi

Cinquanta milioni di investimento digitale e un forte impegno nella tracciabilità dei prodotti

Read all
undefined

Ibi partecipa all'iniziativa UniCredit 4 Growth

Read all

Thank you

We sent you an email. To activate the newsletter click on the link you will find in the message, thank you!

Sign up for the newsletter


Dichiarazione in merito al GDPR (Regolamento Generale Protezione dei Dati)

In caso di sottoscrizione Newsletter dovrai confermare l’iscrizione per mezzo di mail di conferma inviata all’indirizzo inserito. In tal caso il trattamento prevede:

la profilazione dell’utente in gruppi, status, preferenze secondo quanto indicato e dedotto dalle informazioni inviate tramite il form o successiva autonoma profilazione.
l’utilizzo del dato per l’invio di comunicazione a mezzo digitale (email, whatsapp) e non (cartaceo) avente scopo informativo/commerciale.
l'utilizzo della mail per la generazione di campagne marketing e informative personalizzate, digitali e non.

Cancel
CHIUDI


Private area


Log in to restricted area


Registration


Notice on the treatment of personal data

Dear visitor, in the following sections we will describe how the reserved area of the www.ibi-lorenzini.it website is managed as far as processing personal data of users. The notice is issued pursuant to art. 13 of EU Regulation 679/2016 (hereinafter also the Regulation) on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and applies to those who interact with the website of Istituto Biochimico Italiano Giovanni Lorenzini S.p.A. (hereinafter I.B.I.), which can be accessed at the following address: www.ibi-lorenzini.it, the opening page of the official I.B.I. website. The notice only applies to the I.B.I. website. It does not apply to any other websites that the user may access through links.

  1. The processing of the personal data that you supply, which are also used for the creation of your user profile, and which will be included in the “Doctors’ Details” database, has the following purposes:
  • carry out medical sales related activities for drugs for human consumption. Istituto Biochimico Italiano Giovanni Lorenzini S.p.A. and Ibigen S.r.l., part of the same company group (hereinafter also Ibigen Group), carry out such activities in compliance with the provisions of the current regulations, with particular, but not exclusive, attention to Italian Legislative Decree no. 219 of 24.04.2006 and subsequent modifications. In view of the objectives of the Ibigen Group, it is important to point out that the processing activities do not deal with any special data. The supply of the data for the medical sales activities is necessary, and failure to provide consent will make it impossible for us to fulfil the above objectives;

  • forwarding of invitations or information on congresses, conferences, seminars, communications on initiatives promoted or sponsored by the Ibigen group, regular or occasional publications, information on new products, methods and services. Such activities are carried out by e-mail, fax, SMS, normal post or telephone. The supply of the data for such purposes is optional, and failure to supply them will result in the information not being forwarded.

  1. As far as the creation of your profile on our website, we remind you that your password is strictly confidential and should not be disclosed.
  2. Your data will not be disclosed, but may be shared with individuals, companies, associations or professional studios providing support or consultancy services to the Ibigen Group, the medical sales representative network, our suppliers and any sub-suppliers - from time to time entrusted with activities connected with the above objectives -, mailing or statistical survey companies, or companies for the forwarding of scientific documentation, and individuals authorised to access the data by law and/or pursuant to secondary regulations.
  3. Such people may only acquire knowledge of your personal data for the above mentioned purposes.
  4. The Owners of the Treatment (Data Controllers) are the two companies of the Ibigen Group with legal headquarters at Via Fossignano no. 2, Aprilia (LT), Italy.
  5. Personal data are processed using manual and automated means, for the time necessary for reaching the objectives for which they were collected. Special safety measures are in place to avoid data loss, unlawful or incorrect use and unauthorised access.
  6. Lastly, we also inform you that you can at any time exercise the rights contemplated by the Regulation, and in particular request access to the data, their correction, update and block, or you can withdraw your consent, or request the limitation of the processing or the cancellation of the data. As data subject, you also have the right to issue a complaint with the relevant control Authority. Such rights may be exercised in writing to the following e-mail address: info@ibi-lorenzini.com.
  7. The Data Protection Officer may be contacted at the following e-mail address: dpo_ibi@protectiontrade.it

* Required fields
Cancel